Sharmila Anandasabapathy

Dr. Sharmila Anandasabapathy


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
SASharmila Anandasabapathy
Sharmila Anandasabapathy
CAChite Asirwa
Chite Asirwa
SGSurbhi Grover
Surbhi Grover
CMChemtai Mungo
Chemtai Mungo

14 January 2017 in Annual Review of Medicine
Verified
Journal Article
Closed access
NMNabil M. Mansour
Nabil M. Mansour
SGShawn S. Groth
Shawn S. Groth
SASharmila Anandasabapathy
Sharmila Anandasabapathy
Esophageal adenocarcinoma (EAC) is a growing problem with a rapidly rising incidence. Risk factors include gastroesophageal reflux disease, central obesity, and smoking. The prognosis of EAC remains poor because it is usually diagnosed late, and many efforts have been made to improve prevention, early detection, and treatment. Acid suppression, nonsteroidal antiinflammatory drugs (NSAIDs), and statins may play a role in chemoprevention. Screening for Barrett's esophagus (BE), the only known precursor lesion of EAC, is indicated for individuals with increased risk. Endoscopic surveillance of patients with BE likely improves overall outcomes. Endoscopic ablation and resection is highly effective for treating dysplastic BE and early EAC, whereas esophagectomy is indicated for patients with locally advanced disease. This review covers epidemiology, staging, screening, and prevention of EAC as well as endoscopic and surgical management.

4 June 2015 in Best Practice & Research Clinical Gastroenterology
Verified
Journal Article
Closed access
JLJustin S. Louie
Justin S. Louie
RSRicha Shukla
Richa Shukla
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
SASharmila Anandasabapathy
Sharmila Anandasabapathy

1 March 2017 in Annals of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
NMNabil M. Mansour
Nabil M. Mansour
HEHashem B. El-Serag
Hashem B. El-Serag
SASharmila Anandasabapathy
Sharmila Anandasabapathy
Barrett’s esophagus (BE) is a premalignant condition that increases the risk of esophageal adenocarcinoma (EAC). Significantly more common in the Western world, risk factors include increased age, male sex, white race, gastro-esophageal reflux disease (GERD), central obesity, and cigarette smoking. The rates of progression to cancer depend on the grade of Barrett’s dysplasia. Screening for BE is recommended in patients with GERD and additional risk factors. Endoscopic surveillance of patients with BE likely improves overall outcomes. Advanced endoscopic imaging can help increase the efficiency of current endoscopic surveillance. Endoscopic therapy is safe and effective for the treatment of dysplastic BE and intramucosal EAC, but ongoing surveillance following treatment is necessary. This review will cover screening, surveillance, advanced imaging, chemoprevention, endoscopic treatment, and post-treatment surveillance of BE.

1 April 2024 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
XZXiaohui Zhang
Xiaohui Zhang
MTMimi Tan
Mimi Tan
MNMansour Nabil
Mansour Nabil
RSRicha Shukla
Richa Shukla
SVShaleen Vasavada
Shaleen Vasavada
EPElena V. Petrova
Elena V. Petrova
With an incidence of about 600,000 new cases and more than 500,000 deaths annually worldwide, esophageal cancer (EC) is one of the deadliest cancers worldwide. The two main histological subtypes of EC include: esophageal adenocarcinoma1 and esophageal squamous cell carcinoma (ESCC).2 Screening and early detection of ESCC are critically important to help reduce the incidence and mortality associated with EC. However, challenges posed by the extensive surface area of the esophagus, the limited field-of-view (FOV) offered by conventional microendoscopic screening probes (100 to 1000  μm),3 – 5 and the time constraints of endoscopic procedures (6 to 8 min per patient) necessitate the development of an innovative approach to enable imaging of larger fields and improve diagnostic yield.

1 May 2024 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
HHHuayu Hou
Huayu Hou
JCJennifer Carns
Jennifer Carns
RSRichard A. Schwarz
Richard A. Schwarz
AGAnn M. Gillenwater
Ann M. Gillenwater
SASharmila Anandasabapathy
Sharmila Anandasabapathy
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
SignificanceFiber-optic microendoscopy is a promising approach to noninvasively visualize epithelial nuclear morphometry for early cancer and precancer detection. However, the broader clinical application of this approach is limited by a lack of topical contrast agents available for in vivo use.AimThe aim of this study was to evaluate the ability to image nuclear morphometry in vivo with a novel fiber-optic microendoscope used together with topical application of methylene blue (MB), a dye with FDA approval for use in chromoendoscopy in the gastrointestinal tract.ApproachThe low-cost, high-resolution microendoscope implements scanning darkfield imaging without complex optomechanical components by leveraging programmable illumination and the rolling shutter of the image sensor. We validate the integration of our system and MB staining for visualizing epithelial cell nuclei by performing ex vivo imaging on fresh animal specimens and in vivo imaging on healthy volunteers.ResultsThe results indicate that scanning darkfield imaging significantly reduces specular reflection and resolves epithelial nuclei with enhanced image contrast and spatial resolution compared to non-scanning widefield imaging. The image quality of darkfield images with MB staining is comparable to that of fluorescence images with proflavine staining.ConclusionsOur approach enables real-time microscopic evaluation of nuclear patterns and has the potential to be a powerful noninvasive tool for early cancer detection.